查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1678533

全球癫痫治疗市场：市场规模、市场份额、趋势分析（按治疗方法、分销管道和地区）、按细分市场预测（2025-2030 年）

Epilepsy Drugs Market Size, Share & Trends Analysis Report By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

癫痫药物市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球癫痫药物市场规模预计到 2030 年将达到 154.7 亿美元，2025 年至 2030 年的复合年增长率为 5.7%。政府增加对治疗癫痫发作的新有效药物的开发资金是推动癫痫药物市场成长的重要因素。美国癫痫协会 (AES) 与美国神经病学学会、癫痫基金会和格拉斯基金会等其他组织合作，资助研究和开发活动，并透过各种计画为医生提供一系列治疗意识培训。

此外，癫痫基金会、美国癫痫协会、中佛罗里达癫痫协会、治愈癫痫协会和安妮塔考夫曼基金会等组织实施的各种宣传计划正在进一步加快诊断和治疗率。预计这将在预测期内推动市场成长。

癫痫药物市场：概述

  • 第二代抗癫痫药物预计将成为第二快成长速度的领域。此部分包括拉莫三嗪 (Lamictal)、左乙拉西坦 (Keppra)、布瓦莱克坦 (Briviact)、吡崙帕奈 (Fycompa) 等。
  • 第三代抗癫痫药物领域在 2024 年占据最大的销售份额，约 39.7%。该领域成长的主要驱动力包括推出作用机制改进、副作用更少的高效药物，以及即将推出的新药管线。
  • 2024 年北美将占据最大的销售份额，约 38.7%。癫痫的高盛行率和受该疾病影响的人数众多是该地区癫痫药物市场的主要推动要素。
  • 预计预测期内亚太地区的癫痫药物市场将实现显着的复合年增长率。这是因为该地区人口众多且多样化，癫痫盛行率迅速上升，以及医疗保健基础设施不断改善。

目录

第一章 分析方法及范围

第 2 章执行摘要

第三章 癫痫药物市场：驱动因素、趋势与范围

  • 市场联动展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTEL 分析

第 4 章 癫痫药物市场：依治疗方法进行的商业分析

  • 治疗方法的市场占有率（2024 年和 2030 年）
  • 治疗方法仪表板
  • 市场规模预测及治疗方法趋势分析（2018-2030）
  • 第一代抗癫痫药物
  • 第二代抗癫痫药物
  • 第三代抗癫痫药物

第 5 章 癫痫药物市场：按分销管道进行的业务分析

  • 按分销管道分類的市场占有率（2024 年和 2030 年）
  • 分销通路仪表板
  • 按分销管道分類的市场规模预测及趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 其他的

第六章 癫痫药物市场：按地区估计和趋势分析

  • 各地区市场占有率（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 参与企业概况
  • 公司市场地位分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • UCB SA
    • Sanofi
    • Pfizer, Inc.
    • Otsuka America Pharmaceutical, Inc.
    • Eisai Co., Ltd.
    • Abbott Laboratories, Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Sunovion Pharmaceuticals, Inc.
    • Jazz Pharmaceuticals plc
    • Neurelis, Inc.
Product Code: 978-1-68038-958-6

Epilepsy Drugs Market Growth & Trends:

The global epilepsy drugs market size is estimated to reach USD 15.47 billion by 2030, expanding at a CAGR of 5.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights:

  • Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
  • The third generation anti-epileptics segment accounted for the largest revenue share of around 39.7% in 2024. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • North America dominated the market with the largest revenue share of around 38.7% in 2024. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
  • Asia Pacific epilepsy drugs market is expected to register at a notable CAGR over the forecast period, attributed to the large and diverse population of the region, surging prevalence of epilepsy, and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Epilepsy Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Epilepsy Drugs Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Treatment, 2018 to 2030 (USD Million)
  • 4.4. First Generation Anti-epileptics
    • 4.4.1. First Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • 4.5. Second Generation Anti-epileptics
    • 4.5.1. Second Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • 4.6. Third Generation Anti-epileptics
    • 4.6.1. Third Generation Anti-epileptics Market, 2018 - 2030 (USD Million)

Chapter 5. Epilepsy Drugs Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Epilepsy Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. U.K.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. U.K. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Norway Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. UCB S.A.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Sanofi
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Pfizer, Inc.
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Otsuka America Pharmaceutical, Inc.
      • 7.5.4.1. Participant's overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Eisai Co., Ltd.
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Abbott Laboratories, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Novartis AG
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. GlaxoSmithKline plc
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Sunovion Pharmaceuticals, Inc.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Jazz Pharmaceuticals plc
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Neurelis, Inc.
      • 7.5.11.1. Participant's Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Epilepsy Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 5 Global Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8 North America Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 U.S. Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 U.S. Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Canada Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 14 Mexico Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 U.K. Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 U.K. Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Germany Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Germany Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 France Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 France Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Italy Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Italy Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Spain Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27 Spain Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Denmark Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Denmark Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Norway Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31 Norway Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 33 Sweden Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Japan Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 Japan Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 China Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 China Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 India Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42 India Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 South Korea Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 South Korea Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Australia Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 46 Australia Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 48 Thailand Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Latin America Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 Brazil Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 55 Argentina Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 UAE Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 64 UAE Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Epilepsy Drugs Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot

Fig. 9 Treatment and Distribution Channel Outlook (USD Million)

  • Fig. 10 Competitive Landscape
  • Fig. 11 Epilepsy Drugs Market Dynamics
  • Fig. 12 Epilepsy Drugs Market: Porter's Five Forces Analysis
  • Fig. 13 Epilepsy Drugs Market: PESTLE Analysis
  • Fig. 14 Epilepsy Drugs Market: Treatment Segment Dashboard
  • Fig. 15 Epilepsy Drugs Market: Treatment Market Share Analysis, 2024 & 2030
  • Fig. 16 First Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • Fig. 17 Second Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • Fig. 18 Third Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • Fig. 19 Epilepsy Drugs Market: Distribution Channel Segment Dashboard
  • Fig. 20 Epilepsy Drugs Market: Distribution Channel Market Share Analysis, 2024 & 2030
  • Fig. 21 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 22 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 23 Others Market, 2018 - 2030 (USD Million)
  • Fig. 24 Epilepsy Drugs Market Revenue, By Region
  • Fig. 25 Regional Marketplace: Key Takeaways
  • Fig. 26 Regional Marketplace: Key Takeaways
  • Fig. 27 North America Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Country Dynamics
  • Fig. 29 U.S. Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada Country Dynamics
  • Fig. 31 Canada Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico Country Dynamics
  • Fig. 33 Mexico Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 U.K. Country Dynamics
  • Fig. 36 U.K. Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany Country Dynamics
  • Fig. 38 Germany Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Country Dynamics
  • Fig. 40 France Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy Country Dynamics
  • Fig. 42 Italy Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Country Dynamics
  • Fig. 44 Spain Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark Country Dynamics
  • Fig. 46 Denmark Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway Country Dynamics
  • Fig. 48 Norway Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden Country Dynamics
  • Fig. 50 Sweden Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan Country Dynamics
  • Fig. 53 Japan Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 China Country Dynamics
  • Fig. 55 China Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 India Country Dynamics
  • Fig. 57 India Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 South Korea Country Dynamics
  • Fig. 59 South Korea Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Australia Country Dynamics
  • Fig. 61 Australia Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand Country Dynamics
  • Fig. 63 Thailand Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil Country Dynamics
  • Fig. 66 Brazil Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina Country Dynamics
  • Fig. 68 Argentina Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East & Africa Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa Country Dynamics
  • Fig. 71 South Africa Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia Country Dynamics
  • Fig. 73 Saudi Arabia Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE Country Dynamics
  • Fig. 75 UAE Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait Key Country Dynamicss
  • Fig. 77 Kuwait Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 78 Company Categorization
  • Fig. 79 Company Market Position Analysis
  • Fig. 80 Strategic Framework